Abstract:Abstract Background N6-methyladenosine (m6A) is one of the common modifications of transcripts that is regulated by related proteins including writers, readers and erasers. Abnormal m6A modification plays an important role in the process of tumor development. Current approaches for tumor m6A RNA methylation, based on sequencing data from public databases, focus on the comparison of m6A modification regulator expression by RNA-seq data. Results We obtained MeRIP-seq and corresponding RNA-seq data from GEO database to compare and analyze the distributional characteristics of m6A in different types of tumor samples, the differences in m6A modification enrichment, and the regulatory role in gene transcriptional expression level. We found that the enrichment of m6A modification was enhanced in IMPA and GBM tumor samples, but was decreased in METTL3 knockdown tumor cells. Combined with clinical data from the TCGA database, we found that the high expression of DUSP7 significantly affected the overall survival of AML patients and was involved in tumor development through the PIK3R2 protein and MAPK signaling pathways. Conclusion Abnormal m6A modification enrichment in tumor samples leads to dysregulation in the expression of cancer-related genes.

Transcriptional regulatory networks mediated by abnormal m6A modifications in tumor development